Journal: Acta Endocrinologica (Bucharest)

Article Title: EVALUATION OF FETUIN-A LEVELS IN THE EARLY STAGE OF AUTOIMMUNE THYROIDITIS

doi: 10.4183/aeb.2023.301

Figure Lengend Snippet: Evaluation of the performance of fetuin-A in predicting Hashimoto’s thyroiditis using ROC curve analysis

Article Snippet: Serum fetuin-A levels were determined using a human fetuin-A ELISA kit (Elabscience Biotechnology, Houston, TX, USA).

Techniques:

Journal: Pflugers Archiv : European journal of physiology

Article Title: Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels.

doi: 10.1007/s00424-024-03046-4

Figure Lengend Snippet: Fig. 3 Phosphatropic hormones after 5 days of low- or high- phosphate (Pi) diet. Levels of A serum parathyroid hor- mone (PTH), B plasma intact fibroblast growth factor 23 (iFGF23), C plasma C-terminal FGF23 (cFGF23), D the ratio of iFGF23 (ng/l)/cFGF23 (ng/l) as well as serum E calcidiol, and F calcitriol, and G plasma soluble Klotho, and H Fetuin-A on the final day of both the 5-day low and high Pi diet. One reference unit (RU)/ml corre- sponds to 2 ng/l cFGF23. Blue dots represent differences (Δ) between high Pi diet and low Pi diet expressed as mean differ- ence ± 95% confidence interval and blue dashed line represents the zero line of the right y-axis. Data was analyzed by the paired t-test (A–E) or Wilcoxon test (F–H), n = 10, *p < 0.05

Article Snippet: Daily fractional excretion of Pi (FEPi) was calculated by the following equation using the absolute 24-h urine Pi and creatinine: Daily renal filtered Pi load was calculated with the following equation: Plasma iFGF23, cFGF23, Fetuin-A, and urinary metanephrine were measured with the human iFGF23 and cFGF23 enzyme-linked immunosorbent assay (ELISA) (iFGF23 and cFGF23, Quidel, 60–6600 and 60–6100, respectively), Fetuin-A ELISA (R&D Systems, DFTA00, Lot P413286), and the Metanephrine Urine ELISA (Demeditec Diagnostics GmbH, DEE8400) according to manufacturers’ protocols.

Techniques: Clinical Proteomics

Journal: medRxiv

Article Title: Post-translational modifications glycosylation and phosphorylation of the major hepatic plasma protein fetuin-A are associated with severity of CNS inflammation in children

doi: 10.1101/2022.05.04.22274686

Figure Lengend Snippet: shows the results of the concentration measurements of fetuin-A in CSF and serum. The correlation of fetuin-A in serum (y-axis, mg/ml) with an elevated C-reactive protein concentration (x-axis, (A)) and the presence of neuroinflammatory disease (x-axis, (B)) is shown. The relation between fetuin-A in CSF (y-axis, µg/ml) and a disruption of the blood-brain barrier (x-axis) is displayed in (C). (D) and (E) show the connection of the serum fetuin-A / total serum protein ratio (y-axis) with an intrathecal IgG synthesis (x-axis, (D)) and the disruption of the blood-brain barrier (x-axis, (E)). In (F), the link between the CSF fetuin-A / total CSF protein ratio (y-axis) and age (x-axis, years) is shown as a scatter plot. (G) and (H) show the correlation between the CSF fetuin-A / serum fetuin-A ratio QFet (y-axis, x10-3) and the CSF albumin / serum albumin ratio QAlb (x-axis, x10-3, (H)) and the presence of a blood-brain barrier disruption (x-axis, (G)). (G) represents a scatter blot double logarithmically. (H) shows a boxplot.

Article Snippet: For ELISA studies of fetuin-A concentrations we used the Human Fetuin-A/AHSG DuoSet ELISA (R&D Systems, Minneapolis, USA) as well as 96 well plates and solutions from the DuoSet Ancillary Reagent Kit (R&D Systems, Minneapolis, USA) according to the manufacturers’ recommendations.

Techniques: Concentration Assay, Protein Concentration, Disruption

Journal: medRxiv

Article Title: Post-translational modifications glycosylation and phosphorylation of the major hepatic plasma protein fetuin-A are associated with severity of CNS inflammation in children

doi: 10.1101/2022.05.04.22274686

Figure Lengend Snippet: illustrates the results of the glycosylation studies of fetuin-A. (A) and (B) show the glycosylation patterns of fetuin-A with (A) and without (B) double bands. On each membrane, lane 1 shows undigested fetuin-A, lane 2 shows fetuin-A after PNGase-F digestion and lane 3 shows fetuin-A after sialidase-Au digestion. (C) compares the occurrence of double bands in the control group and inflammatory group as a bar chart. (D) displays the kinetic of PNGase-F digestion in serum and CSF. Lane 1 shows undigested fetuin-A, lane 2 shows the pattern after 1 minute of digestion, lane 3 displays the pattern after 10 minutes of digestion and lane 4 shows fetuin-A after 3 hours of PNGase-F digestion.

Article Snippet: For ELISA studies of fetuin-A concentrations we used the Human Fetuin-A/AHSG DuoSet ELISA (R&D Systems, Minneapolis, USA) as well as 96 well plates and solutions from the DuoSet Ancillary Reagent Kit (R&D Systems, Minneapolis, USA) according to the manufacturers’ recommendations.

Techniques: Membrane

Journal: medRxiv

Article Title: Post-translational modifications glycosylation and phosphorylation of the major hepatic plasma protein fetuin-A are associated with severity of CNS inflammation in children

doi: 10.1101/2022.05.04.22274686

Figure Lengend Snippet: displays the results of the statistical analysis of the phosphorylation studies. (A) and (B) show relative CSF phospho fetuin-A concentrations (y-axis, %) in comparison to the CSF albumin / serum albumin ratio (A, x-axis, x10-3) and in the presence of neuroinflammatory diseases (B). (C) and (D) show absolute phospho fetuin-A levels in CSF (y-axis, µg/ml) in comparison to the CSF albumin / serum albumin ratio ((C), x-axis, ×10 −3 ) and a blood-brain barrier disruption ((D), x-axis). (E) and (D) display the results of the linear regression with the relative CSF phospho fetuin-A / relative serum phospho fetuin-A ratio. This ratio is shown on the y-axis. (E) shows a scatter plot with the CSF albumin / serum albumin ratio (x-axis, ×10 −3 ). (F) shows the correlation of the CSF phospho fetuin-A / serum phospho fetuin-A ratio with the presence of a neuroinflammatory disorder (x-axis).

Article Snippet: For ELISA studies of fetuin-A concentrations we used the Human Fetuin-A/AHSG DuoSet ELISA (R&D Systems, Minneapolis, USA) as well as 96 well plates and solutions from the DuoSet Ancillary Reagent Kit (R&D Systems, Minneapolis, USA) according to the manufacturers’ recommendations.

Techniques: Comparison, Disruption

Journal: Virchows Archiv : an international journal of pathology

Article Title: Immunohistochemical localization and mRNA expression of matrix Gla protein and fetuin-A in bone biopsies of hemodialysis patients.

doi: 10.1007/s00428-008-0724-4

Figure Lengend Snippet: Fig. 4 Fetuin-A, IHC: a osteoblasts with variable intensity of positivity are present (arrows); b osteoblasts are highly positive (arrows). In both a and b, endosteal fibrosis cells (asterisks) and some osteocytes (arrowheads) are positive, while osteoclasts are negative (empty arrows); a clear positivity of calcified bone matrix is visible, while the osteoid seams are negative (white asterisks). Trabecular bone, hyperparathyroidism. Bars=20 μm

Article Snippet: Then, the goat anti-human fetuin-A/AHSG polyclonal antibody (R&D Systems, Inc; Minneapolis, MN, USA) was applied (1:500 dilution) for 1 h. Immunodetection was performed using the LSAB2 System-HRP kit (DakoCytomation, Inc., Carpinteria, CA, USA).

Techniques:

Journal: Virchows Archiv : an international journal of pathology

Article Title: Immunohistochemical localization and mRNA expression of matrix Gla protein and fetuin-A in bone biopsies of hemodialysis patients.

doi: 10.1007/s00428-008-0724-4

Figure Lengend Snippet: Fig. 5 Fetuin-A, ISH: a, b Osteoblasts (arrows) and some osteocytes (arrowheads) and endosteal fibrosis cells (asterisks) are positive. In b, a negative osteoclast is present (empty arrow). Trabecular bone, hyperparathyroidism. Bars=20 μm

Article Snippet: Then, the goat anti-human fetuin-A/AHSG polyclonal antibody (R&D Systems, Inc; Minneapolis, MN, USA) was applied (1:500 dilution) for 1 h. Immunodetection was performed using the LSAB2 System-HRP kit (DakoCytomation, Inc., Carpinteria, CA, USA).

Techniques:

Journal: Journal of pharmacy and pharmacology research

Article Title: Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468

doi: 10.26502/fjppr.0103

Figure Lengend Snippet: Overexpression of fetuin-A (Fet-A) in MDA-MB-468 TNBC cell line. MDA-MB-468 cells were transfected with either empty vector (EV) or flag-tagged fetuin-A expression vector (FA). Fetuin-A expression level was determined by QT-RTPCR (panel A), Western blot (panel B) and IHC (panel C) as described in .

Article Snippet: Primary mouse monoclonal anti-human fetuin-A/AHSG antibody (R&D Systems, MAB1184) was used at a dilution of 1:500 in Antibody OP Quanto antibody diluent (Thermo Fisher, TA-125-ADQ).

Techniques: Over Expression, Transfection, Plasmid Preparation, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot

Journal: Journal of pharmacy and pharmacology research

Article Title: Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468

doi: 10.26502/fjppr.0103

Figure Lengend Snippet: Enhanced invasion capacity in fetuin-A overexpressing MDA—MB-468 cells. The MDA-MB-468-FA invaded through a bed of Matrigel more readily compared to MDA-MB-468-EV when complete medium (CM) was in the lower compartment of the trans-well (*P<0.05); N=6). Both sub-clones did not invade when SFM was in the lower compartments (controls) (**P<0.001; N=6)

Article Snippet: Primary mouse monoclonal anti-human fetuin-A/AHSG antibody (R&D Systems, MAB1184) was used at a dilution of 1:500 in Antibody OP Quanto antibody diluent (Thermo Fisher, TA-125-ADQ).

Techniques: Clone Assay

Journal: Journal of pharmacy and pharmacology research

Article Title: Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468

doi: 10.26502/fjppr.0103

Figure Lengend Snippet: Toll like receptor 4 (TLR4) expression in MDA-MB-468 sub-clones. Surface TLR4 expression levels were determined by flow cytometry in MDA-MB-468-EV (upper panels) and MDA-MB-468-FA (lower panels) in the absence and presence of added fetuin-A (FA)

Article Snippet: Primary mouse monoclonal anti-human fetuin-A/AHSG antibody (R&D Systems, MAB1184) was used at a dilution of 1:500 in Antibody OP Quanto antibody diluent (Thermo Fisher, TA-125-ADQ).

Techniques: Expressing, Clone Assay, Flow Cytometry

Journal: Journal of pharmacy and pharmacology research

Article Title: Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468

doi: 10.26502/fjppr.0103

Figure Lengend Snippet: Fetuin-A mediates 2-D and 3-D growth of MDA-MB-468 via TLR4 signaling. The cells were seeded (2 × 10 4 cells/well) in attachment (2-D) ( panel A ) or ultra-low attachment (3-D) ( panel B ) 96-well plates in SFM; SFM + CLI-095 (CLI); Fetuin-A (FA); FA + CLI; complete medium (CM); and in CM + CLI. After 6 days of growth, Alamar blue was added to each well, incubated for 2 h and fluorescence measured as described. *P< 0.05; **P< 0.001; ***P<0.0001; N= 4

Article Snippet: Primary mouse monoclonal anti-human fetuin-A/AHSG antibody (R&D Systems, MAB1184) was used at a dilution of 1:500 in Antibody OP Quanto antibody diluent (Thermo Fisher, TA-125-ADQ).

Techniques: Incubation, Fluorescence

Journal: Journal of pharmacy and pharmacology research

Article Title: Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468

doi: 10.26502/fjppr.0103

Figure Lengend Snippet: In A , control chambers had only cells in SFM, while experimental chambers had CLI-095 (28 µM) in SFM (upper chambers) of trans-well assay. The bottom chambers had complete medium (CM). In B , controls had CM only in the bottom chambers while experimental chambers had CM depleted of fetuin-A (CM + HA). Number of invading cells was determined as described in .

Article Snippet: Primary mouse monoclonal anti-human fetuin-A/AHSG antibody (R&D Systems, MAB1184) was used at a dilution of 1:500 in Antibody OP Quanto antibody diluent (Thermo Fisher, TA-125-ADQ).

Techniques: Control